Havana, Nov 16 (Prensa Latina) In the coming years Cuba could present a new group of therapeutic vaccines against different types of cancer, foresaw the Director of the Cuban Center of Molecular Immunology (CIM) Agustin Lage.

   According to the scientist, the monoclonal antibody against cancer HR3 is presently among the products in advanced development by that entity.

   Participants in the 2006 International Immunotherapy Event taking place in the Cuban capital exchanged experiences with the results of the clinical tests of HR3 in China and India, where it has helped to treat head and neck tumors and pharynx carcinoma.

    Similarly the institution works on clinical tests of the antibody T1, a provisional name for the treatment of self-immune diseases, and of another against breast cancer.

   In addition, the CIM has another five similar products under pre-clinical tests.

   Therapeutic vaccines against cancer have been relatively unpopular in world clinical practice, but Lage highlighted that Cuba counts on a group of them in different test phases on humans.

(Prensa Latina)